Buy Now: Neurostimulation

Report Description

The global market for neurostimulation products is expected to be worth $3.6 billion in 2009, growing at a CAGR of 22.7%, driven by the multiple treatment applications of neurostimulation products, and the emergence of venture capital in the industry.

Neurostimulation is used for the treatment of several debilitating conditions, including major treatment-resistant depression, epilepsy, gastroparesis, hearing loss, incontinence, chronic pain, Parkinson’s disease, and essential tremors. Neurostimulation systems provide an improved lifestyle alternative to many patients who do not obtain relief from standard drug and invasive surgical therapy.

The neurostimulation market is driven mainly by technology advancements, rising consumer awareness, rising age-related neurological disorders, improved clinical outcomes, long-term cost-effectiveness, increased FDA approvals for clinical trials, and the development of sophisticated implantable neurostimulation devices. Currently, there is a huge influx of new players entering into the market, thus leading to increased investments and R&D activities.

Implantable neurostimulation devices are increasingly being used for the treatment of a number of chronic disorders such as pain management and epilepsy. Manufacturers are employing developments in low-power semiconductor design, improved manufacturing procedures, and longer battery life for such devices to offer effective, efficient, and long-lasting neurostimulation products. Innovative products such as closed-loop system neurostimulator are designed to continuously stimulate the nervous system.

SCOPE AND FORMAT

The report analyzes the global biomarker market into the following segments:

• Product Market (spinal cord stimulator, deep brain stimulator, vagus nerve stimulator, sacral nerve stimulator, and gastric electrical stimulator )
• Application Market (Alzheimer’s, Parkinson’s, chronic heart failure, essential tremors, eye disorders, paralysis, obesity, and other medical conditions )
• Technology  Market (minimally-invasive and non-invasive stimulation technology )

The market data consists of aggregate sales figures of all neurostimulation submarkets. It analyzes the market aspects of new neurostimulation technologies and product launches; sourcing key market developments from the top companies that it profiles. The report also analyzes the documented claims and the neurostimulation technology patents approved over the last five years to provide an in-depth understanding of neurostimulation product and applications.

What makes our report unique?

The existing studies and third-party market reports do not provide a comprehensive understanding of the neurostimulation market. The critical markets within this broader field are also not analyzed. This report gives a detailed analysis of the overall market as well as its most critical micro-markets, which have so far remained unexplored. In addition to the comprehensive information on the macro-markets, the report provides market data for up to five levels of the micro-markets under these identified macro markets. Other reports cover only the major technologies or products; and miss out subsequent micro levels.

Key questions answered

• Which are the high growth markets segments in terms of products, applications, and technology?
• What are the market forecasts and estimates from the period 2009-14?
• What are the major drivers and opportunities in the market?
• What is the competitive outlook, what are the major products and applications, who are the major players in the market segments?

Table of  Content

1. INTRODUCTION
1.1.    KEY TAKE-AWAYS
1.2.    REPORT DESCRIPTION
1.3.    MARKETS COVERED
1.4.    STAKEHOLDERS
2. THE NERVOUS SYSTEM
2.1. TYPES OF NERVOUS SYSTEM DISORDERS
2.2.    BRAIN DISORDERS
2.2.1. Seizures/epilepsy
2.2.2. Alzheimer’s Disease
2.3.    SACRAL NERVE DISORDERS
2.4.    NEUROSTIMULATION TREATMENTS FOR NEURO-DISORDERS
3. MARKET OVERVIEW OF GLOBAL NEUROSTIMULATION MARKET
3.1.    DEFINING THE NEUROSTIMULATION PRODUCT MARKET
3.2.    VALUE CHAIN ANALYSIS FOR NEUROSTIMULATION MARKET
3.2.1. DEMAND-SIDE DRIVERS
3.2.1.1. Longer lasting effect and shorter hospital stays
3.2.1.2. Minimally-invasive technology
3.2.1.3. Caters to the needs of the aging population
3.2.2. SUPPLY-SIDE DRIVERS
3.2.2.1. New market entrants and technology developments
3.2.2.2. Extensive marketing dynamics
3.2.3. RESTRAINTS
3.2.3.1. High cost of treatment and lack of surgical skill
3.2.3.2. Post-treatment side-effects and prolonged regulatory approvals
3.2.4. OPPORTUNITIES
3.2.4.1. Increasing awareness of neurostimulation in developing countries
3.2.4.2. Gaps in the demand and supply cycle
3.2.5. KEY COMPETITIVE POINTS
3.2.5.1. Improved outcomes at competitive prices
3.2.5.2. Better brand advertising for treatments and products
3.3.    PRODUCT LIFECYCLE & MARKET DYNAMICS
3.3.1. Promotional strategies
3.3.2. Channel distribution strategies
3.4.    DEFINING THE NEUROSTIMULATION APPLICATIONS MARKET
3.5.    NEUROSTIMULATION TECHNOLOGY MARKET
3.5.1. SPINALCORD STIMULATOR DRIVING THE NEUROSTIMULATION PRODUCT MARKET
3.5.2. ALZHEIMER’S AND PARKINSON’S DRIVING THE NEUROSTIMULATION APPLICATIONS MARKET
4. GLOBAL NEUROSTIMULATION PRODUCT MARKET
4.1.    DRIVERS
4.1.1. PORTABILITY, USER-FRIENDLINESS, & WIDE-RANGING APPLICATIONS
4.1.2. INCREASING INTEREST OF VENTURE CAPITAL FIRMS
4.1.3. EXTENSIVE PROMOTIONAL STRATEGIES OF MAJOR MARKET PLAYERS
4.2.    SPINAL CORD STIMULATOR
4.2.1. DRIVERS
4.2.1.1. High efficiency in the treatment of chronic pain
4.2.1.2. Cost benefits of spinal cord stimulation
4.2.2. BONE GROWTH STIMULATOR
4.2.3. SPINAL CORD FUSION STIMULATOR
4.3.    DEEP BRAIN STIMULATOR
4.3.1. DRIVERS
4.3.1.1. Risk-less & flexible alternative to surgery
4.4.    VAGUS NERVE STIMULATOR
4.5.    SACRAL NERVOUS STIMULATOR
4.5.1. DRIVERS
4.5.1.1. Increase in incidence of urinal and incontinence disorders
4.5.1.2. Shortening of surgical time increases revenues for stakeholders
4.6.    GASTRIC ELECTRICAL STIMULATOR
4.6.1. DRIVERS & RESTRAINTS
4.6.1.1. Advantages over conventional treatment
4.6.1.2. Gastric stimulation requires special surgical expertise
5. NEUROSTIMULATION APPLICATION MARKET
5.1.    DRIVERS & RESTRAINTS
5.1.1. ADVANTAGES OVER CONVENTIONAL SURGERY
5.1.2. INCREASE IN AGING POPULATION
5.1.3. COST FACTOR & INSUFFICIENT EXPERTISE
5.2.    ALZHEIMER’S DISEASE
5.2.1. DRIVERS
5.2.1.1. Memory improvement & fewer side-effects
5.2.1.2. Absence of an alternate cure for Alzheimer’s
5.3.    PARKINSON’S DISEASE
5.4.    PAIN
5.4.1. ACUTE PAIN
5.4.2. CHRONIC PAIN
5.4.2.1. Drivers
5.4.2.2. Migraine
5.4.2.3. Other chronic pain
5.5.    CHRONIC HEART FAILURE (CHF)
5.5.1. DRIVERS
5.6.    STROKE
5.6.1. EPILEPSY
5.6.2. DEPRESSION
5.6.2.1. Drivers & Restraints
5.6.3. OTHERS STROKES
5.7.    PARALYSIS
5.8.    OBESITY
5.8.1. DRIVERS
5.8.1.1. Increased accuracy in treating morbid obesity
5.8.1.2. Reduced cost of hospital stays
5.9.    ESSENTIAL TREMORS
5.10. EYE DISORDERS
5.10.1. SECOND SIGHT DISORDERS
5.10.2.    OTHER EYE DISORDERS
5.11. OTHER NEUROSTIMULATION APPLICATIONS
5.12. GASTROPARESIS
5.13. INCONTINENCE
6. GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET
6.1.    DRIVERS
6.2.    MINIMALLY-INVASIVE STIMULATION
6.2.1. MAGNETIC NERVE STIMULATION
6.2.1.1. Drivers
6.2.1.1.1. Better treatment than anti-depression drugs
6.2.1.1.2. Technology developments supporting market growth
6.2.2. TRANSCUTANEOUS ELECTRICAL NEUROSTIMULATION
6.2.3. OTHERS MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY
7. GEOGRAPHIC ANALYSIS
7.1.    NORTH AMERICA
7.2.    EUROPE
7.3.    ASIA
7.4.    ROW
8. COMPETITIVE LANDSCAPE
9. NEUROSTIMULATION PATENT ANALYSIS
10. NEUROSTIMULATION COMPANY PROFILES
10.1. CYBERONICS, INC.
10.2. DYNATRONICS
10.3. ELEKTA AB
10.4. ENTEROMEDICS, INC.
10.5. GI DYNAMICS
10.6. H. LUNDBECK
10.7. IMPULSE DYNAMICS
10.8. INNOVATIVE NEUROTRONICS, INC.
10.9. INTEGRA LIFE SCIENCES HOLDINGS CORPORATION
10.10. MEDTRONIC, INC
10.11. NDI MEDICAL
10.12. NEURONETICS, INC.
10.13. NEUROPACE
10.14. NEUROTECH
10.15. NEXSTIM
10.16. RS MEDICAL
10.17. ST. JUDE MEDICAL, INC.
10.18. SYNAPSE BIOMEDICAL
10.19. THE MAGSTIM COMPANY LIMITED
10.20. VERTIS NEUROSCIENCE
APPENDIX
LIST OF TABLES
TABLE 1 GLOBAL NEUROSTIMULATION MARKET, BY PRODUCT 2007 – 2014 ($MILLIONS)
TABLE 2 GLOBAL NEUROSTIMULATION PRODUCT MARKET, BY GEOGRAPHY 2007 – 2014($ MILLIONS)
TABLE 3 GLOBAL SPINAL CORD STIMULATOR MARKET, BY PRODUCT 2009 – 2014 ($ MILLIONS)
TABLE 4 GLOBAL SPINAL CORD STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 5 GLOBAL BONE GROWTH STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 6 GLOBAL SPINAL CORD FUSION STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 7 GLOBAL DEEP BRAIN STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 8 GLOBAL VAGUS NERVE STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 9 GLOBAL SACRAL NERVE STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 10 GLOBAL GASTRIC ELECTRICAL STIMULATOR MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 11 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET 2007 – 2014 ($ MILLIONS)
TABLE 12 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 13 GLOBAL ALZHEIMER’S NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 14 GLOBAL PARKINSON’S NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 15 GLOBAL NEUROSTIMULATION PAIN APPLICATIONS MARKET 2007 – 2014 ($ MILLIONS)
TABLE 16 GLOBAL PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 17 GLOBAL ACUTE PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 18 GLOBAL CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 19 GLOBAL CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 20 GLOBAL MIGRAINE NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 21 GLOBAL OTHER CHRONIC PAIN NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 22 GLOBAL CHRONIC HEART FAILURE NEUROSTIMULATION MARKET,  BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 23 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR STROKE,  BY GEOGRAPHY  2007 – 2014 ($ MILLIONS)
TABLE 24 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR STROKE,  BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 25 GLOBAL NEUROSTIMULATION MARKET FOR EPILEPSY, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 26 GLOBAL NEUROSTIMULATION MARKET FOR DEPRESSION, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 27 GLOBAL NEUROSTIMULATION MARKET FOR OTHER STROKES, BY GEOGRAPHY 2007 – 2014($ MILLIONS
TABLE 28 GLOBAL NEUROSTIMULATION MARKET FOR PARALYSIS, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 29 GLOBAL NEUROSTIMULATION MARKET FOR OBESITY, BY GEOGRAPHY  2007 – 2014 ($ MILLIONS)
TABLE 30 GLOBAL NEUROSTIMULATION MARKET FOR ESSENTIAL TREMORS, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 31 GLOBAL NEUROSTIMULATION APPLICATIONS MARKET FOR EYE DISEASES  2007 – 2014 ($ MILLIONS)
TABLE 32 GLOBAL NEUROSTIMULATION MARKET FOR EYE DISEASES, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 33 GLOBAL NEUROSTIMULATION MARKET FOR SECOND SIGHT, BY GEOGRAPHY  2007 – 2014 ($ MILLIONS)
TABLE 34 GLOBAL NEUROSTIMULATION MARKET FOR OTHER EYE DISORDERS,  BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 35 GLOBAL OTHER NEUROSTIMULATION  APPLICATIONS MARKET 2007 – 2014($ MILLIONS)
TABLE 36 GLOBAL OTHER NEUROSTIMULATION APPLICATIONS MARKET, BY GEOGRAPHY 2007 – 2014($ MILLIONS)
TABLE 37 GLOBAL NEUROSTIMULATION MARKET FOR GASTROPARESIS, BY GEOGRAPHY   2007 – 2014($ MILLIONS)
TABLE 38 GLOBAL NEUROSTIMULATION MARKET FOR INCONTINENCE, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 39 GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET, BY PRODUCT 2007 – 2014 ($ MILLIONS)
TABLE 40 GLOBAL NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 41 GLOBAL MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY MARKET, BY PRODUCT 2007 – 2014 ($ MILLIONS)
TABLE 42 GLOBAL MINIMALLY-INVASIVE NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 – 2014($ MILLIONS)
TABLE 43 GLOBAL MINIMALLY-INVASIVE MAGNETIC NERVE NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 44 GLOBAL MINIMALLY-INVASIVE TRANSCUTANEOUS ELECTRICAL NEUROSTIMULATION TECHNOLOGY MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 45 GLOBAL OTHER MINIMALLY-INVASIVE NEUROSTIMULATION MARKET, BY GEOGRAPHY 2007 – 2014 ($ MILLIONS)
TABLE 46 REGULATORY APPROVALS IN THE NEUROSTIMULATION MARKET (2008-2009)
TABLE 47 NEW PRODUCT DEVELOPMENTS IN THE NEUROSTIMULATION MARKET  (2008-2009)
TABLE 48 NEUROSTIMULATION PATENTS FILED FROM 2004 TO JUNE 2009
LIST OF FIGURES
FIGURE 1 NEUROSTIMULATION PRODUCT MARKET BY TOTAL MARKET SIZE  (2007 – 2014)
FIGURE 2 VALUE CHAIN ANALYSIS FOR NEUROSTIMULATION MARKET
FIGURE 3 PRODUCT LIFE CYCLE GRAPH OF NEUROSTIMULATION MARKET
FIGURE 4 NEUROSTIMULATION APPLICATIONS MARKET
FIGURE 5 NEUROSTIMULATION PRODUCT MARKET SHARE AND MARKET     GROWTH MATRIX ANALYSIS
FIGURE 6 NEUROSTIMULATION APPLICATION MARKET SHARE AND MARKET GROWTH RATE MATRIX ANALYSIS 2009
FIGURE 7 GEOGARPHICAL MARKET ANALYSIS OF THE PRODUCT MARKET (2009)
FIGURE 8 REGULATORY APPROVALS IN THE NEUROSTIMULATION MARKET (2008-2009)
FIGURE 9 NEW PRODUCT LAUNCHES IN THE NEUROSTIMULATION MARKET (2008-2009)
FIGURE 10 NEUROSTIMULATION PATENTS FILED WORLDWIDE (2004 TO JUNE 2009)
FIGURE 11 NEUROSTIMULATION PATENTS FILED WORLDWIDE FOR DIFFERENT CATEGORIES (2004 TO JUNE 2009)
FIGURE 12 NEUROSTIMULATION PATENTS FILED IN NORTH AMERICA (2004 TO JUNE 2009)
FIGURE 13 NEUROSTIMULATION PATENTS FILED IN EUROPE (2004 TO JUNE 2009)
FIGURE 14 NEUROSTIMULATION PATENTS FILED IN ASIA (2004 TO JUNE 2009)
The Global Neurostimulation Market report analyzes the neurostimulation product, technology and application market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global neurostimulation market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions.
Neurostimulation is used for the treatment of several debilitating conditions, including major treatment-resistant depression, epilepsy, gastroparesis, hearing loss, incontinence, chronic pain, Parkinson’s disease, and essential tremors. Neurostimulation systems provide an improved lifestyle alternative to many patients who do not obtain relief from standard drug and invasive surgical therapy.
Neurostimulation Article
The neurostimulation market is driven mainly by technology advancements, rising consumer awareness, rising age-related neurological disorders, improved clinical outcomes, long-term cost-effectiveness, increased FDA approvals for clinical trials, and the development of sophisticated implantable neurostimulation devices. Currently, there is a huge influx of new players entering into the market, thus leading to increased investments and R&D activities.
The global market for neurostimulation products is expected to be worth $3.6 billion in 2009, and expected to reach $10.2 billion by 2014, driven by the multiple treatment applications of neurostimulation products, and the emergence of venture capital in the industry. Neurostimulation treatment involves less risk of infection, pain, bleeding, and swelling. These factors are encouraging an ever-increasing number of patients to opt for this treatment which is driving the market.
Neurostimulation application Market share and Market growth rate Matrix analysis 2009


alzheimer’s and Parkinson’s driving the neurostimulation applications market
The above figure illustrates the relative market shares and growth for the various neurostimulation applications in 2009. Alzheimer’s and Parkinson’s applications have relatively high market size and high growth rate, thereby promising huge potential market for the major market players. Pain, chronic heart failure, and the strokes applications markets have an average market share but relative high growth rate; and are thus witnessing increased number of new entrants. Obesity, others neurodisorders (incontinence and gastroparesis) applications currently have low market shares but very high growth rates; while the essential tremors and eye disorder applications have low market shares and low growth rates.